Background Many urgent and elective surgeries were postponed to cope with the Coronavirus disease (COVID-19) pandemic, with latest data found a substantial postoperative mortality risk (25·6%, 18.9%) after emergency and elective surgery, respectively. Our institution was one of the first trust to offer essential elective surgery using a “COVID-free” designated site during the start of the pandemic. The aim of this study is to analyse the clinical outcomes of patients who underwent essential elective procedures during the virus outbreak in the UK. Method Retrospective analysis of outcomes all patients who had undergone urgent elective and cancer surgery, from 30th March 2020 to 21st May 2020, using an implemented “Super Green Pathway”. The primary endpoints were 30 days mortality and COVID related morbidities, and the secondary endpoints were surgical related complications and oncological outcomes. Results 92 patients (Male:45%; Female:55%) across 5 surgical specialties were identified. There was no record of mortality in our cohort. Only 1 patient was tested positive for SARS-CoV-2, 18 days after the initial operation without any pulmonary complications. Conclusions It is possible to mitigate the high mortality risk of postoperative complications associated with COVID-19, with no delay to essential surgeries for cancer patients, thus delivering safe practice during the pandemic.

No abstract

This paper is a review of Oman's major Health Information Systems (HISs) and their enabling technologies. The work assesses the scope, functionality, security, and interoperability of the used systems. The review aids in achieving the objectives of HIS systems of improving the global quality of health care, attaining increased coordination between health care providers and consumers, promoting the use of guidelines and policies, and improving the speed of simultaneous access and distribution of medicalrecords and other resources. This paper, which can be considered as a building block towards the development of a nation-wide health care system, studies existing systems and identifies their functions and structures.

Myofibroblastoma (MFB) is an extremely rare benign tumor that can arise in various organs, but commonly in the breast. Albeit it is a benign tumor, the diagnosis is frequently challenging with insurmountable difficulties as it might be erroneously diagnosed as a malignancy. Herein we are reporting a large-sized MFB presented as a non-tender, firm mass which interestingly was adherent to the skin and was initially thought as cancer. The patient underwent a wide local excision and histology confirmed MFB, and had no evidence of recurrence up to 8 months post-operatively.

No abstract

No abstract

Non-muscle invasive bladder cancer (NMIBC) is a common urological malignancy, and bacillus Calmette-Guérin (BCG) therapy is the gold standard treatment in intermediate and high-risk groups. However, BCG failure occurs in a significant proportion of patients, emphasizing the need for effective alternative treatment modalities to address this burden. These treatments include immunotherapy, enhanced drug delivery, targeted therapy, device-assisted chemotherapy, vaccine therapy, and gene therapy, which show varying degrees of safety and efficacy. The objective of this review is to summarize the current evidence and ongoing research on these emerging therapies, offering insight into their potential for improving patient outcomes and quality of life. Although radical cystectomy remains the standard of care for high-risk NMIBC patients unresponsive to BCG, novel treatment modalities hold promise for the future management of this challenging patient population.

No abstract